Table 3 Associations between molecular subtypes and clinicopathologic variables in the validation cohort
From: Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Variable | N | Overall | sTRU (n = 74) | sPP (n = 102) | sPI (n = 83) | EGFR/TP53 (n = 74) | KRAS/TP53 (n = 50) | Non-TRUPPPI (n = 38) | No mutation (n = 63) | P |
|---|---|---|---|---|---|---|---|---|---|---|
Age, mean (standard deviation), y | 484 | 63.7 (10.4) | 66.4 (9.1) | 65.9 (9.4) | 63.2 (9.3) | 59.1 (11.9) | 64.1 (8.5) | 63.7 (11.7) | 62.7 (12.2) | < 0.001 |
Race/ethnicity, n (%) | 484 |  |  |  |  |  |  |  |  | < 0.001a |
 Asian |  | 40 (8.3) | 13 (17.6) | 2 (2.0) | 4 (4.8) | 14 (18.9) | 0 (0.0) | 1 (2.6) | 6 (9.5) |  |
 Black |  | 36 (7.4) | 2 (2.7) | 11 (10.8) | 6 (7.2) | 6 (8.1) | 3 (6.0) | 2 (5.3) | 6 (9.5) |  |
 White |  | 372 (76.9) | 54 (73.0) | 80 (78.4) | 71 (85.5) | 44 (59.5) | 40 (80.0) | 35 (92.1) | 48 (76.2) |  |
 Hispanic |  | 31 (6.4) | 5 (6.8) | 8 (7.8) | 2 (2.4) | 7 (9.5) | 6 (12.0) | 0 (0.0) | 3 (4.8) |  |
 Other |  | 5 (1.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 3 (4.1) | 1 (2.0) | 0 (0.0) | 0 (0.0) |  |
Sex, n (%) | 484 | Â | Â | Â | Â | Â | Â | Â | Â | 0.022 |
 Female |  | 280 (57.9) | 49 (66.2) | 65 (63.7) | 37 (44.6) | 43 (58.1) | 32 (64.0) | 25 (65.8) | 29 (46.0) |  |
 Male |  | 204 (42.1) | 25 (33.8) | 37 (36.3) | 46 (55.4) | 31 (41.9) | 18 (36.0) | 13 (34.2) | 34 (54.0) |  |
Smoking, n (%) | 484 |  |  |  |  |  |  |  |  | < 0.001a |
 Current |  | 60 (12.4) | 2 (2.7) | 22 (21.6) | 14 (16.9) | 4 (5.4) | 8 (16.0) | 3 (7.9) | 7 (11.1) |  |
 Former |  | 270 (55.8) | 26 (35.1) | 69 (67.6) | 55 (66.3) | 29 (39.2) | 39 (78.0) | 25 (65.8) | 27 (42.9) |  |
 Never |  | 154 (31.8) | 46 (62.2) | 11 (10.8) | 14 (16.9) | 41 (55.4) | 3 (6.0) | 10 (26.3) | 29 (46.0) |  |
Alcohol, n (%) | 478 | Â | Â | Â | Â | Â | Â | Â | Â | 0.476a |
 Current |  | 174 (36.4) | 30 (41.1) | 36 (35.3) | 29 (36.2) | 26 (35.1) | 16 (32.0) | 16 (42.1) | 21 (34.4) |  |
 Former |  | 91 (19.0) | 12 (16.4) | 21 (20.6) | 14 (17.5) | 7 (9.5) | 14 (28.0) | 10 (26.3) | 13 (21.3) |  |
 Never |  | 177 (37.0) | 28 (38.4) | 35 (34.3) | 31 (38.8) | 33 (44.6) | 17 (34.0) | 12 (31.6) | 21 (34.4) |  |
 Social |  | 36 (7.5) | 3 (4.1) | 10 (9.8) | 6 (7.5) | 8 (10.8) | 3 (6.0) | 0 (0.0) | 6 (9.8) |  |
 Tumor size, mean (standard deviation), cm | 449 | 3.86 (2.28) | 3.78 (2.05) | 4.36 (2.81) | 3.80 (2.16) | 3.27 (1.69) | 3.97 (2.20) | 3.43 (2.00) | 4.05 (2.44) | 0.234 |
Metastatic, n (%) | 275 | Â | Â | Â | Â | Â | Â | Â | Â | 0.018 |
 No |  | 150 (54.5) | 20 (38.5) | 38 (69.1) | 20 (47.6) | 20 (45.5) | 16 (59.3) | 12 (66.7) | 24 (64.9) |  |
 Yes |  | 125 (45.5) | 32 (61.5) | 17 (30.9) | 22 (52.4) | 24 (54.5) | 11 (40.7) | 6 (33.3) | 13 (35.1) |  |
Mucinous, n (%) | 121 |  |  |  |  |  |  |  |  | < 0.001 |
 0 |  | 91 (75.2) | 21 (95.5) | 20 (57.1) | 11 (78.6) | 10 (100.0) | 11 (100.0) | 3 (37.5) | 15 (71.4) |  |
 1 |  | 30 (24.8) | 1 (4.5) | 15 (42.9) | 3 (21.4) | 0 (0.0) | 0 (0.0) | 5 (62.5) | 6 (28.6) |  |
Lepidic, n (%) | 121 | Â | Â | Â | Â | Â | Â | Â | Â | 0.063 |
 0 |  | 71 (58.7) | 8 (36.4) | 21 (60.0) | 10 (71.4) | 7 (70.0) | 10 (90.9) | 5 (62.5) | 10 (47.6) |  |
 1 |  | 50 (41.3) | 14 (63.6) | 14 (40.0) | 4 (28.6) | 3 (30.0) | 1 (9.1) | 3 (37.5) | 11 (52.4) |  |
Acinar, n (%) | 121 | Â | Â | Â | Â | Â | Â | Â | Â | 0.012 |
 0 |  | 78 (64.5) | 17 (77.3) | 28 (80.0) | 8 (57.1) | 4 (40.0) | 5 (45.5) | 7 (87.5) | 9 (42.9) |  |
 1 |  | 43 (35.5) | 5 (22.7) | 7 (20.0) | 6 (42.9) | 6 (60.0) | 6 (54.5) | 1 (12.5) | 12 (57.1) |  |
Micro/papillary, n (%) | 121 | Â | Â | Â | Â | Â | Â | Â | Â | 0.175 |
 0 |  | 106 (87.6) | 21 (95.5) | 31 (88.6) | 14 (100.0) | 7 (70.0) | 10 (90.9) | 6 (75.0) | 17 (81.0) |  |
 1 |  | 15 (12.4) | 1 (4.5) | 4 (11.4) | 0 (0.0) | 3 (30.0) | 1 (9.1) | 2 (25.0) | 4 (19.0) |  |
Solid, n (%) | 121 | Â | Â | Â | Â | Â | Â | Â | Â | 0.143 |
 0 |  | 103 (85.1) | 20 (90.9) | 30 (85.7) | 11 (78.6) | 9 (90.0) | 6 (54.5) | 8 (100.0) | 19 (90.5) |  |
 1 |  | 18 (14.9) | 2 (9.1) | 5 (14.3) | 3 (21.4) | 1 (10.0) | 5 (45.5) | 0 (0.0) | 2 (9.5) |  |
Mixed, n (%) | 121 | Â | Â | Â | Â | Â | Â | Â | Â | 0.492 |
 0 |  | 88 (72.7) | 19 (86.4) | 26 (74.3) | 9 (64.3) | 8 (80.0) | 8 (72.7) | 6 (75.0) | 12 (57.1) |  |
 1 |  | 33 (27.3) | 3 (13.6) | 9 (25.7) | 5 (35.7) | 2 (20.0) | 3 (27.3) | 2 (25.0) | 9 (42.9) |  |
Primary, n (%) | 428 | Â | Â | Â | Â | Â | Â | Â | Â | 0.056 |
 0 |  | 233 (54.4) | 39 (56.5) | 40 (47.1) | 41 (57.7) | 30 (46.2) | 21 (45.7) | 22 (62.9) | 40 (70.2) |  |
 1 |  | 195 (45.6) | 30 (43.5) | 45 (52.9) | 30 (42.3) | 35 (53.8) | 25 (54.3) | 13 (37.1) | 17 (29.8) |  |
Stage, n (%) | 483 |  |  |  |  |  |  |  |  | < 0.001a |
 I |  | 118 (24.4) | 20 (27.0) | 26 (25.5) | 14 (16.9) | 19 (26.0) | 16 (32.0) | 11 (28.9) | 12 (19.0) |  |
 II |  | 46 (9.5) | 1 (1.4) | 19 (18.6) | 5 (6.0) | 4 (5.5) | 4 (8.0) | 4 (10.5) | 9 (14.3) |  |
 III |  | 108 (22.4) | 12 (16.2) | 29 (28.4) | 27 (32.5) | 11 (15.1) | 9 (18.0) | 5 (13.2) | 15 (23.8) |  |
 IV |  | 211 (43.7) | 41 (55.4) | 28 (27.5) | 37 (44.6) | 39 (53.4) | 21 (42.0) | 18 (47.4) | 27 (42.9) |  |
FISH, n (%) | 453 | Â | Â | Â | Â | Â | Â | Â | Â | 0.042 |
 Negative |  | 402 (88.7) | 64 (90.1) | 92 (96.8) | 65 (83.3) | 63 (88.7) | 35 (81.4) | 32 (86.5) | 51 (87.9) |  |
 Positive |  | 51 (11.3) | 7 (9.9) | 3 (3.2) | 13 (16.7) | 8 (11.3) | 8 (18.6) | 5 (13.5) | 7 (12.1) |  |